Clinical Study

Nrg-Gu006- A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial Of Salvage Radiotherapy With Or Without Enhanced Anti-Androgen Therapy With Apalutamide In Recurrent Prostate Cancer.

Posted Date: May 15, 2019

  • Investigator: Timothy Struve
  • Specialties: Cancer, Oncology, Prostate Cancer
  • Type of Study: Drug

To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone


To Be Eligible: Age 18 Or Older, Must Have Prostate Cancer And Have Had A Prostatectomy,No Current Metastatic Disease,


Prostate Cancer, Phase Ii, Oncology

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.